| Eye disease |
Drug nanoparticles |
| Corneal Disease |
IM-CS-NPs, CS-CsA-SLN, DS-NS, CS/
TCS-SA NPs |
| Keratoplasty |
FK506 PLGA |
| Corneal neovascularization |
Flt23k NPs, Pluronic F 127 diacrylate |
| Viral keratitis |
SLNs, NLCs |
| Wounds of the corneal epithelium |
All-trans retinoic acid NPs |
| Corneal gene therapy |
Chitosan-DNA NPs, deliver plasmid |
| Corneal tissue engineering |
Nanofibrous tissue-engineered scaffolds |
| Glaucoma |
HDNP, CS-HA-NPs, (SLN)NPs |
| Uveitis |
PEG-block-PLA, NP-PEG-TAM |
| Retinal diseases |
Aerosolized NPs,
Vacancy engineered mixed-valence-state
cerium oxide NPs |
| Retinal gene therapy |
VMD2-eGFP, PEG-POD NPs, Compacted
DNA NPs |
| Age-related macular degeneration |
PEG-LPH-NP siRNA, PLA/PLA-PEO NPs |
| Choroidal neovascularization |
bFGF-NPs, (CK30PEG)-compacted DNA
NPs |
CS, chitosan; CsA, cyclosporine A; HA, Hyaluronic acid; HDNP, hybrid dendrimer
nanoparticle; IM, indomethacin; LPH, liposomeprotamine-hyaluronic acid; LC, lipid
carrier; NPs, Nanoparticles; NS, nanoparticle suspensions; PEG, poly (ethylene)
glycol; PEO, polyethylene oxide; PLA, poly (lactic acid); PLGA, poly (lactic-coglycolic
acid); SA, sodium alginate; SL, solid lipid; TAM, tamoxifen; TCS, thiolated
chitosan; VMD2-eGFP, retinal pigment epithelium-specific reporter vector; SLN,
solid lipid nanoparticles; |